To investigate the efficacy and safety of the single center flow diverter Surpass Streamline in the treatment of unruptured aneurysms.

The clinical data of 39 patients with unruptured aneurysms treated with Surpass Streamline from December 2020 to August 2022 in the cerebrovascular disease diagnosis and treatment center of Zhuhai People's Hospital were analyzed retrospectively. There were 45 aneurysms in 39 patients, including 23 in the ocular segment, 6 in the traffic segment, 5 in the cavernous sinus segment, 4 in the clinoid process segment, 4 in the V4 segment, 2 in the petrous segment, and 1 in the cervical segment.

39 patients were implanted with 39 Surpass Streamlines, the success rate of stent release was 100%, 38 patients (97.4%) were satisfied with the release effect, 1 patient bridged the stent due to poor adhesion, 38 aneurysms were followed up for the first time within 3.8 ± 1.4 months after operation, 30 patients (78.9%) in OKM grade D, 7 patients (18.4%) in grade C,and 1 patient (2.7%) in grade B, 6 patients (18.8%) had stent restenosis (4 patients were mild, 2 patients were moderate), but there was no obvious blood flow restriction. A total of 16 aneurysms in 15 patients were followed up 12.1 ± 2.3 months after operation, and 15 (93.8%) were of OKM grade D. Among them,2 patients with restenosis (1 mild, 1 moderate) were followed up for the first time, and the original stenosis was basically completely recovered and the lumen was well displayed after 1 year of follow-up.

Surpass Streamline is safe and effective in the treatment of unruptured aneurysms. Stent restenosis generally does not affect the blood flow and the healing of aneurysms, and has a certain degree of self-limiting. The short-term and medium-term follow-up is satisfactory, and still needs to be verified by further large sample, multi-center and long-term follow-up research.